Gemini bioproducts:1110293 [18-009950]
Ended Awarded Last action
- Contract number
- 75N95018F00001
- Awardee
-
Gemini Bioproducts LLC UEI TPLGWKT6AM88
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,765
Award facts
- Contract value 100% obligated
- $7,764.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 3 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Baltimore, MD 21224, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$25 | |
| Original award | $7,790 |
About this award
This is a firm fixed-price BPA (Blanket Purchase Agreement) call awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Gemini Bioproducts LLC, a for-profit manufacturer of cell culture products, sera, antibiotics, media, reagents, and blood/blood products. The contract has a ceiling value of $7,764.80 and an ultimate completion date of May 31, 2019. Gemini Bioproducts is a key supplier of critical biological products for federal research institutions, particularly within the biomedical research ecosystem. The company has a track record of supplying high-quality cell culture materials to various federal agencies, including significant contributions to COVID-19 research. This award is not associated with a set-aside program. Gemini Bioproducts also holds two significant IDIQ (Indefinite Delivery/Indefinite Quantity) contracts, one with FEMA for COVID-19 testing supplies worth up to $200 million, and another with the Office of Logistics and Acquisition Operations for cell culture products, sera, antibiotics, media, reagents, and blood-related products worth up to $100 million, demonstrating the company's capability to quickly respond to urgent national needs.
Quick answers
Who was awarded contract 75N95018F00001?
75N95018F00001 was awarded to Gemini Bioproducts LLC by National Institute on Drug Abuse (National Institutes of Health) on June 25, 2018.
How much is contract 75N95018F00001 worth?
The government has obligated $7,765 on 75N95018F00001.
Is contract 75N95018F00001 an order under another contract?
Yes. 75N95018F00001 is a BPA call under HHSN263201500189B, a blanket purchase agreement.
Was contract 75N95018F00001 competed?
The extent of competition for 75N95018F00001 was competed under sap. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award